Phoenix Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Phoenix Financial’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-366,364	Closed	-$30.2M	–	372
2024 Q2	$30.2M	Sell	366,364 -25,675	-7%	-$2.14M	0.46%	43
2024 Q1	$34.2M	Buy	392,039 +31,882	+9%	+$2.85M	0.47%	47
2023 Q4	$38.8M	Buy	+360,157	New	+$31.9M	0.64%	41
2021 Q4	–	Sell	-25,764	Closed	-$1.97M	–	385
2021 Q3	$1.97M	Sell	25,764 -5,807	-18%	-$458K	0.03%	211
2021 Q2	$2.63M	Buy	31,571 +4,306	+16%	+$341K	0.05%	194
2021 Q1	$2.04M	Buy	+27,265	New	+$2.23M	0.05%	219

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Phoenix Financial's BMRN Position: Q3 2024 in Review

Phoenix Financial sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 366,364 shares — an estimated $30.2M sold.

Phoenix Financial first reported a position in BMRN in Q1 2021 and held it in 6 quarters. The position peaked at $38.8M in Q4 2023. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Phoenix Financial reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Phoenix Financial sold 366,364 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $30.2M.
Phoenix Financial first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 6 quarters.
Phoenix Financial's BioMarin Pharmaceuticals position peaked at $38.8M in Q4 2023.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Phoenix Financial's 13F filing for Q3 2024, filed 5 Nov 2024.